BRAF and metastatic melanoma: As BRAF inhibition is potent against metastatic melanoma, but allows for recurrence in time, we ultimately set out to determine to what extent this peptide could be complementary to the clinically frequently prescribed BRAFV600E-inhibitor PLX4032, Vemurafenib.